Sign in Create account

Dr. Reddy's Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: DRREDDY BSE: 500124
₹1233.00
▼ -18.90 (-1.51%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
62/100
Moderate
Valuation
33/100
Fairly Valued
Momentum
71/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Source: Wikipedia

Key Metrics

Market Capitalization
₹102,916 Cr
PE (TTM)
154.7
Industry median 36.1 (152 companies)
Price to Book
2.7
PEG (TTM)
-1.7
Institutions holding %
63.81%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
-3.1
Relative return vs Sector, qtr %
-8.0
Free Cash Flow
₹3,343 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-86.34%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-44.24%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-28.80%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-86.33%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-34.23%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.80
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.16
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
5.02
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
7.88%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
11.10%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
5.68%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
7.15%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
13.90%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
10.87%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.16)
  • No Return on equity is 15% or more (10.9%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.5%
Low 1214.2000 · High 1244.6000
1W return
1.8%
Low 1193.4000 · High 1252.8000
1M return
6.8%
Low 1130.0000 · High 1252.8000
52W return
-0.9%
Low 1101.0000 · High 1414.9000
Lifetime High ₹7062.4500 (Aug. 21, 2024)
Lifetime Low ₹155.4000 (Dec. 5, 1996)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish5
Bearish1
5D
1225.2
10D
1209.9
20D
1194.5
50D
1196.1
100D
1215.7
200D
1247.3

Delivery and volume

Day avg. delivery
64.6%
Week avg. delivery
54.2%
Month avg. delivery
55.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1230.60
Pivot
First resistance1247.00
Second resistance1261.00
Third resistance1277.40
First support1216.60
Second support1200.20
Third support1186.20
Day RSI62.4
Day MFI66.9
Day MACD14.02
Day MACD signal4.97

Beta

1M0.50
3M0.25
1Y0.48
3Y0.42

Price change analysis

↑ 6.8%
Over 1 Month
LowHigh
1130.001252.80
↓ -8.0%
Over 3 Months
LowHigh
1101.001390.40
↑ 1.9%
Over 6 Months
LowHigh
1101.001414.90
↓ -0.9%
Over 1 Year
LowHigh
1101.001414.90
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 154.7 (own history: 7.7–170.3)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹5,137 Cr
Net profit (June 30, 2026)
₹405 Cr
Basic EPS (June 30, 2026)
₹4.8600

Ranks #8 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter26.64%
  • Mutual funds13.16%
  • FII/FPI32.07%
  • Other DII18.58%
  • Public9.35%

Largest holders

NameCategoryShares %Shares
LIFE INSURANCE CORPORATION OF INDIA P & GS FUNDPublic12.1600%101502343
GVP Family TrustPromoter11.5100%96095920
J P Morgan Chase Bank NAPublic11.4100%95244276
VSD Family TrustPromoter9.0600%75630620
ICICI PRUDENTIAL VALUE DISCOVERY FUNDPublic4.4100%36842838

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings increased from 26.63% to 26.64% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 33.08% to 32.07% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 13.19% to 13.16% in Jun 2026 qtr

62 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 1536 insider trades, 61 SAST, 10 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
30 Mar 2026 Patrick Aghanian Other Buy 0 ₹0
12 Dec 2025 Tricia Wetzel Other Buy 0 ₹0
17 Sep 2025 Patrick Aghanian Other Buy 0 ₹0
2 Sep 2025 Anjum Swaroop Other Buy 0 ₹0
4 Aug 2025 C Swaminathan Other Sell 0 ₹0
4 Aug 2025 C Swamynathan Other Sell 0 ₹0
24 Jun 2025 Milan Kalawadia Other Buy 0 ₹0
24 Jun 2025 Jeff Jorgenson Other Buy 0 ₹0
18 Jun 2025 Lalitha Subramanian Other Buy 0 ₹0
18 Jun 2025 Tricia Wetzel Other Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 127 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
9 Sep 2025 KAPITALFORENINGEN PENSAM INVEST Block Sell 581,268 1250.6000 NSE
9 Sep 2025 KAPITALFORENINGEN INVESTIN PRO Block Buy 581,268 1250.6000 NSE
9 Sep 2025 KAPITALFORENINGEN PENSAM INVEST Block Sell 581,268 1250.6000 NSE
9 Sep 2025 KAPITALFORENINGEN INVESTIN PRO Block Buy 581,268 1250.6000 NSE
14 Jul 2025 THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828 Block Sell 141,606 1254.0000 NSE
14 Jul 2025 THE MTBJ LTD. AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849 Block Buy 141,606 1254.0000 NSE
26 Mar 2024 BOFA SECURITIES EUROPE SA Block Sell 260,000 6184.8500 BSE
26 Mar 2024 BOFA SECURITIES EUROPE SA Block Buy 260,000 6184.8500 BSE
18 Jan 2024 JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED Block Sell 31,907 5645.4500 BSE
18 Jan 2024 THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Buy 31,907 5645.4500 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Dr. Reddy's Laboratories Ltd. to Dr. Reddy's Laboratories Ltd.

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
22 Jul 2026 Financial Results Yes
12 May 2026 Dividend —
12 May 2026 Financial Results Yes
21 Jan 2026 Financial Results Yes
24 Oct 2025 Financial Results Yes

Corporate Announcements

All 8 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
3 Oct 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
21 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
18 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
16 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
10 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
10 Sep 2026 Company Update Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.16)
  • Healthy liquidity (Current Ratio 1.80)

Weaknesses

  • Declining revenue YoY (-34.2%)
  • Declining profit YoY (-86.3%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (154.7) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 100, NIFTY 100, NIFTY 200, NIFTY 200, NIFTY 50, NIFTY 50, NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Dr. Reddy's Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.